StoneX Group Inc. Acquires Shares of 15,615 Tempus AI, Inc. (NASDAQ:TEM)

StoneX Group Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, Holdings Channel reports. The institutional investor bought 15,615 shares of the company’s stock, valued at approximately $527,000.

Several other hedge funds have also recently modified their holdings of the stock. Farther Finance Advisors LLC acquired a new position in Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC raised its position in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Tempus AI by 207.9% in the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock worth $55,000 after buying an additional 1,108 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Tempus AI during the fourth quarter worth about $67,000. Finally, IFP Advisors Inc acquired a new position in Tempus AI during the fourth quarter worth about $76,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Performance

Shares of TEM stock opened at $49.89 on Thursday. The company has a 50-day moving average of $58.62 and a two-hundred day moving average of $51.55. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.75, for a total value of $190,363,747.50. Following the completion of the transaction, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. The trade was a 39.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Bradley A. Keywell sold 170,720 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the sale, the insider now directly owns 15,993,729 shares in the company, valued at $566,977,693.05. This represents a 1.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,601,969 shares of company stock valued at $317,330,782.

Analysts Set New Price Targets

A number of research firms have weighed in on TEM. JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. William Blair restated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Bank of America upped their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.